Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health

The privately held Swiss company scored two big FDA approvals at the tail end of 2022. There was the Clostridioides difficile (C. diff) treatment Rebyota, which became the first FDA-approved fecal microbiota product. A few weeks later came the nod for the vector-based gene therapy Adstiladrin, the first approved for bladder cancer.